Hypertension Diagnostics, Inc.

HDIIOTCFinancial Services● Active

$0.00

+$0.00(+0.00%)

Market Cap$13681

P/E Ratio—

52W High$0.0002

52W Low$0.0001

Avg Volume50K

Open$0.00

Beta-53.23

Free Cash Flow Financials Revenue

Hypertension Diagnostics, Inc. (HDII) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

HDII · free cash flow · updated Jun 9, 2026

Core FCF metrics

HDII · FCF · TTM · margin & CAGR

Free cash flow was −$892,257 for FY2021 (fiscal year ending 2021-12-31), down 8011.4% year-over-year

FY2021 Free Cash Flow−$892,257▼ -8011.4% YoY

Trailing 12M (TTM)−$1.3Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

HDII · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2021Latest−$892,257(0M)−$892,257▼ 8011.4%—

FY2020−$11,000(0M)−$11,000▼ 100.3%—

FY2019$3.5M(0M)$3.5M▲ +991.8%—

FY2018−$389,278(0M)−$391,389▼ 345.0%-10.3%

FY2017−$85,919(0M)−$87,952▲ +77.3%-2.4%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

HDII · P/FCF · FCF yield · FCF per share

Hypertension Diagnostics, Inc. (HDII) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2021 · 2021-12-31

Cash flow statement summary

HDII · cash flow statement · operating / investing / financing

For FY2021, Hypertension Diagnostics, Inc. generated −$0.9M in operating cash flow and spent 0M in capital expenditures, yielding −$0.9M in free cash flow.

Operating Activities

−$0.9M

Cash from core business operations

2021-12-31

Investing Activities

+$0.6M

CapEx, acquisitions & investments

2021-12-31

Financing Activities

+$0.2M

Buybacks, dividends & debt

2021-12-31

FCF FormulaOperating CF (−$0.9M) − |CapEx| (0M) = FCF (−$0.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Financial Services)

HDII vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Hypertension Diagnostics, Inc.YOU

HDII

−$892,257-8011.4%—

Loss

Berkshire Hathaway Inc.

BRK-B

$25.04B+115.6%6.7%

25%

Berkshire Hathaway Inc.

Mastercard Incorporated

$16.91B+18.2%51.6%

17%

Financial Services · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Hypertension Diagnostics, Inc. (HDII) reported free cash flow of −$892,257 for FY2021 (fiscal year ending 2021-12-31), down 8011.4% year-over-year.

Based on available data, Hypertension Diagnostics, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $3.5M in FY2019.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

HDII free cash flow · 8 questions

Hypertension Diagnostics, Inc. free cash flow was −$892,257 for FY2021, down 8011.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$1.3M.

HDII free cash flowHDII FCFHDII FCF 2021HDII free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Hypertension Diagnostics, Inc. · Hypertension Diagnostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026